ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements
Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.
Hester Biosciences Limited shareholders approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public' category via postal ballot.
Hester Biosciences delivered strong standalone Q1 growth with revenues up 14% and profit up 88%. Consolidated profit surged 459% due to an INR 853.49 million exceptional gain from a loan amendment.
Hester Biosciences Ltd reported revenue from operations of ₹77.2 Cr (-8.2% YoY) and net profit of ₹96.7 Cr (+459.0% YoY) for Q1 FY27.
Hester Biosciences reported Q4 and FY26 results with consolidated revenue growth of 22% and substantial PAT increase. Strategy focuses on biologicals, capacity utilization, and African market expansion.
Hester Biosciences reported FY26 consolidated revenue of ₹3,325.99 Mn (₹332.60 Cr) and PAT of ₹57.48 Cr, focusing on global expansion in animal and poultry vaccines.
Hester Biosciences delivered a strong Q3 FY26 with standalone revenue up 12% and PAT up 140%, driven by robust Poultry Healthcare performance and operational leverage despite Animal Healthcare headwinds.
Hester Biosciences Ltd reported revenue from operations of ₹100.1 Cr (+22.2% YoY) and net profit of ₹16.5 Cr (+1000.0% YoY) for Q4 FY26.